AR065074A1 - Peptidos de senalizacion - Google Patents

Peptidos de senalizacion

Info

Publication number
AR065074A1
AR065074A1 ARP080100355A ARP080100355A AR065074A1 AR 065074 A1 AR065074 A1 AR 065074A1 AR P080100355 A ARP080100355 A AR P080100355A AR P080100355 A ARP080100355 A AR P080100355A AR 065074 A1 AR065074 A1 AR 065074A1
Authority
AR
Argentina
Prior art keywords
peptides
seq
polypeptide
peptide
interest
Prior art date
Application number
ARP080100355A
Other languages
English (en)
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of AR065074A1 publication Critical patent/AR065074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Péptidos de secuencia especificada y su uso como péptido de senal o un péptido de anclaje a la membrana. También está relacionada con un polipéptido quimérico que comprende uno o más de estos péptidos y un polipéptido de interés así como también moléculas de ácidos nucleicos, vectores, partículas virales infecciosas y células huésped que codifican tales péptidos y polipéptidos quiméricos. También se relaciona con una composicion farmacéutica que comprende tales elementos y un vehículo farmacologicamente aceptable. Proporciona un método para producir por recombinacion un polipéptido utilizando tales péptidos, especialmente para dirigir la expresion de un polipéptido de interés en forma extracelular o anclado a la superficie de la membrana. Reivindicacion 1: Un péptido seleccionado del grupo que consiste de péptidos que esencialmente consisten de, o que consisten de las secuencias de aminoácidos que se muestran en la SEC ID N°1; SEC ID N°:2, SEC ID N° 3, SEC ID N° 4 y SEC ID N°:5
ARP080100355A 2007-05-15 2008-01-29 Peptidos de senalizacion AR065074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07360020 2007-05-15

Publications (1)

Publication Number Publication Date
AR065074A1 true AR065074A1 (es) 2009-05-13

Family

ID=39367596

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100355A AR065074A1 (es) 2007-05-15 2008-01-29 Peptidos de senalizacion

Country Status (13)

Country Link
US (1) US8415462B2 (es)
EP (1) EP2160402A2 (es)
JP (1) JP2010526548A (es)
KR (1) KR20100021603A (es)
CN (1) CN101743250A (es)
AR (1) AR065074A1 (es)
AU (1) AU2008250521B2 (es)
CA (1) CA2687304A1 (es)
IL (1) IL202120A (es)
MX (1) MX2009012326A (es)
PE (1) PE20090683A1 (es)
TW (1) TW200844230A (es)
WO (1) WO2008138649A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2239330A1 (en) 2009-04-07 2010-10-13 Institut Pasteur Neuron generation, regeneration and protection
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
ES2651922T3 (es) * 2011-11-08 2018-01-30 Institut Pasteur Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
MX366206B (es) 2012-07-10 2019-07-02 Transgene Sa Vacuna de antígeno micobacteriano.
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
IL271558B2 (en) 2017-06-21 2024-01-01 Transgene A vaccine tailored to the individual
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06141873A (ja) * 1992-03-13 1994-05-24 Chemo Sero Therapeut Res Inst Ｃ型肝炎ウイルス構成ポリぺプチドをコードする遺伝子が組み込まれたウイルスベクターおよびその利用方法
JPH1023899A (ja) * 1996-07-10 1998-01-27 Nippon Seibutsu Kagaku Kenkyusho 有用蛋白質の生産方法
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US20030059799A1 (en) * 2001-07-11 2003-03-27 Takashi Okuda Modified DNA molecule, recombinant containing the same, and uses thereof
AU2008209759B2 (en) * 2007-01-30 2013-03-21 Transgene S.A. Papillomavirus E2 polypeptide used for vaccination
AU2008250520B2 (en) * 2007-05-15 2013-10-31 Transgene S.A. Vectors for multiple gene expression

Also Published As

Publication number Publication date
KR20100021603A (ko) 2010-02-25
WO2008138649A2 (en) 2008-11-20
EP2160402A2 (en) 2010-03-10
AU2008250521A1 (en) 2008-11-20
TW200844230A (en) 2008-11-16
JP2010526548A (ja) 2010-08-05
WO2008138649A3 (en) 2009-01-08
IL202120A0 (en) 2010-06-16
IL202120A (en) 2013-08-29
US8415462B2 (en) 2013-04-09
AU2008250521B2 (en) 2013-04-18
CN101743250A (zh) 2010-06-16
PE20090683A1 (es) 2009-06-27
US20100160227A1 (en) 2010-06-24
MX2009012326A (es) 2010-02-10
CA2687304A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AR065074A1 (es) Peptidos de senalizacion
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
AR114339A1 (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR066885A1 (es) Proteinas de fusion natriureticas
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
WO2021198706A3 (en) Coronavirus vaccines
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
JP2015524403A5 (es)
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
ATE490266T1 (de) In zellen eindringende peptide als träger für moleküle
WO2008113970A3 (en) Peptides
IL209595A (en) Isolated nucleic acid, expression vector and host cell containing it, isolated polypeptide encoded by it and chimeric polypeptide containing it, process for preparation, oligopeptide hhipl l2 mimics loop, preparations containing it and methods for its production
HRP20190544T1 (hr) Ciklični analozi apelina

Legal Events

Date Code Title Description
FB Suspension of granting procedure